Pay vs Performance Disclosure - USD ($)
|
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Pay vs Performance [Table Text Block] |
|
Pay Versus Performance
As required by Section 953(a) of the Dodd-Frank Wall Street Reform
and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship
between executive “compensation actually paid” and certain financial performance of the Company. For further information
regarding our pay for performance philosophy and how we align executive compensation with the Company’s performance, refer
to the “Compensation Discussion and Analysis” on page 45.
| | |
| | |
| | |
| | |
| | |
Value of Initial Fixed $100
Investment Based on: | | |
| | |
| |
| Year | |
Summary
Compensation
Table Total for
Mr. O’Day(1) | | |
Compensation
Actually Paid to
Mr. O’Day(2) | | |
Average
Summary
Compensation
Table Total for
Other NEOs(3) | | |
Average
Compensation
Actually Paid
to
Other NEOs(4) | | |
Total
Shareholder
Return(5) | | |
Peer Group
Total
Shareholder
Return(6) | | |
Net Income
(in millions)(7) | | |
Net Product
Revenue
(in millions)(8) | |
| 2023 | |
$ | 22,607,690 | | |
$ | 15,483,783 | | |
$ | 7,588,163 | | |
$ | 5,469,137 | | |
$ | 147 | | |
$ | 119 | | |
$ | 5,613 | | |
$ | 26,934 | |
| 2022 | |
$ | 21,621,253 | | |
$ | 54,965,255 | | |
$ | 7,874,828 | | |
$ | 18,182,586 | | |
$ | 150 | | |
$ | 114 | | |
$ | 4,566 | | |
$ | 26,982 | |
| 2021 | |
$ | 19,229,466 | | |
$ | 31,485,348 | | |
$ | 6,279,776 | | |
$ | 9,693,178 | | |
$ | 121 | | |
$ | 126 | | |
$ | 6,201 | | |
$ | 27,008 | |
| 2020 | |
$ | 18,998,095 | | |
$ | 16,117,322 | | |
$ | 6,616,768 | | |
$ | 6,126,435 | | |
$ | 93 | | |
$ | 126 | | |
$ | 89 | | |
$ | 24,355 | |
| (1) |
The dollar amounts reported are the amounts reported in the “Total” column
of the Summary Compensation Table for our Chairman and Chief Executive Officer, Mr. O’Day. |
| (2) |
The dollar amounts reported represent the amount of “compensation actually paid”, as
computed in accordance with SEC rules, for Mr. O’Day. The dollar amounts do not reflect the actual amount of compensation
earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were made to total compensation
to determine the compensation actually paid: |
| (3) |
The dollar amounts reported represent the average of the amounts reported for
our NEOs as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable
year. The NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2023
and 2022, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Deborah H. Telman; and (ii) for 2021 and 2020, Andrew
D. Dickinson, Johanna Mercier, Merdad V. Parsey and Brett A. Pletcher. |
| (4) |
The dollar amounts reported represent the average amount of “compensation
actually paid” to the NEOs identified in footnote 3, as computed in accordance with SEC rules. The dollar amounts do
not reflect the actual amount of compensation earned by or paid to any NEO during the applicable year. In accordance with
the SEC rules, the following adjustments were made to average total compensation for the NEOs for each year to determine the
compensation actually paid: |
| (5) |
Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement
period, assuming dividend reinvestment, and the difference between our share price at the end of each year shown and the beginning
of the measurement period by our share price at the beginning of the measurement period. The beginning of the measurement
period for each year in the table is December 31, 2019. |
| (6) |
The peer group used for this purpose is the Nasdaq Biotechnology Index. |
| (7) |
The dollar amounts reported represent the amount of net income reflected in our Consolidated Statements of Income included
in our Annual Report on Form 10-K for the applicable year. Included in our net income for 2020 was a $4.5 billion charge to
acquired in-process research and development (“IPR&D”) expense recorded in connection with our acquisition
of Forty Seven, Inc. Our 2022 net income included a $2.7 billion partial impairment charge related to certain IPR&D assets
acquired from Immunomedics, Inc. |
| (8) |
The dollar amounts reported represent the amount of net product sales revenue reflected in our Consolidated Statements
of Income included in our Annual Report on Form 10-K for the applicable year. Total full year 2023 product sales of $26.9
billion were relatively flat compared to the same period in 2022, with lower Veklury sales largely offset by higher HIV and
Oncology sales. Total product sales, excluding Veklury, increased 7% to $24.7 billion in the full year 2023 compared to 2022,
primarily driven by higher HIV and Oncology sales. |
| (1) |
The dollar amounts reported are the amounts reported in the “Total” column
of the Summary Compensation Table for our Chairman and Chief Executive Officer, Mr. O’Day. |
| (2) |
The dollar amounts reported represent the amount of “compensation actually paid”, as
computed in accordance with SEC rules, for Mr. O’Day. The dollar amounts do not reflect the actual amount of compensation
earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were made to total compensation
to determine the compensation actually paid: |
| |
Year | |
Summary
Compensation Table
Total for Mr. O’Day | | |
Less: Summary
Compensation
Table Reported
Value of Equity
Awards(a) | | |
Plus: Equity Award
Adjustments(b) | | |
Equals: Compensation
Actually Paid to Mr. O’Day | |
| |
2023 | |
$ | 22,607,690 | | |
$ | 15,615,056 | | |
$ | 8,491,149 | | |
$ | 15,483,783 | |
| |
2022 | |
$ | 21,621,253 | | |
$ | 14,353,915 | | |
$ | 47,697,917 | | |
$ | 54,965,255 | |
| |
2021 | |
$ | 19,229,466 | | |
$ | 13,139,064 | | |
$ | 25,394,946 | | |
$ | 31,485,348 | |
| |
2020 | |
$ | 18,998,095 | | |
$ | 11,513,097 | | |
$ | 8,632,324 | | |
$ | 16,117,322 | |
| |
(a) |
Represents the aggregate grant-date fair value of equity awards as reported in the
“Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year. |
| |
(b) |
The equity award adjustments for each applicable year were as set forth in the table below. The
valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The
amounts deducted or added in calculating the equity award adjustments are as follows: |
| |
Year | |
Year End
Fair Value of
Equity Awards
Granted during
the Year | | |
Year over Year
Change in Fair Value
of Outstanding and
Unvested Equity Awards
Granted in Prior Years | | |
Year over Year Change
in Fair Value of Equity
Awards Granted
in Prior Years that
Vested in the Year | | |
Value of Dividend
Equivalents Accrued
or Other Earnings Paid
on Stock Awards Not
Otherwise Reflected
in Fair Value | | |
Total Equity
Award
Adjustments | |
| |
2023 | |
$ | 12,525,814 | | |
$ | (2,481,113) | | |
$ | (2,859,625) | | |
$ | 1,306,073 | | |
$ | 8,491,149 | |
| |
2022 | |
$ | 34,153,918 | | |
$ | 14,183,571 | | |
$ | (1,966,582) | | |
$ | 1,327,010 | | |
$ | 47,697,917 | |
| |
2021 | |
$ | 17,162,219 | | |
$ | 6,011,125 | | |
$ | 707,262 | | |
$ | 1,514,340 | | |
$ | 25,394,946 | |
| |
2020 | |
$ | 8,885,442 | | |
$ | (1,693,496) | | |
$ | 409,911 | | |
$ | 1,030,467 | | |
$ | 8,632,324 | |
| (3) |
The dollar amounts reported represent the average of the amounts reported for
our NEOs as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable
year. The NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2023
and 2022, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Deborah H. Telman; and (ii) for 2021 and 2020, Andrew
D. Dickinson, Johanna Mercier, Merdad V. Parsey and Brett A. Pletcher. |
| (4) |
The dollar amounts reported represent the average amount of “compensation
actually paid” to the NEOs identified in footnote 3, as computed in accordance with SEC rules. The dollar amounts do
not reflect the actual amount of compensation earned by or paid to any NEO during the applicable year. In accordance with
the SEC rules, the following adjustments were made to average total compensation for the NEOs for each year to determine the
compensation actually paid: |
| |
Year | |
Average
Reported Summary
Compensation Table
Total for Other NEOs | | |
Less: Summary
Compensation Table
Average Reported
Value of Equity Awards | | |
Plus: Average
Equity Award
Adjustments(a) | | |
Equals: Average
Compensation Actually
Paid to Other NEOs | |
| |
2023 | |
$ | 7,588,163 | | |
$ | 4,809,225 | | |
$ | 2,690,199 | | |
$ | 5,469,137 | |
| |
2022 | |
$ | 7,874,828 | | |
$ | 4,961,052 | | |
$ | 15,268,810 | | |
$ | 18,182,586 | |
| |
2021 | |
$ | 6,279,776 | | |
$ | 3,625,534 | | |
$ | 7,038,936 | | |
$ | 9,693,178 | |
| |
2020 | |
$ | 6,616,768 | | |
$ | 3,087,064 | | |
$ | 2,596,731 | | |
$ | 6,126,435 | |
| |
(a) |
The amounts deducted or added in calculating the total average equity award adjustments are as follows: |
| |
Year | |
Average Year End
Fair Value of Equity
Awards Granted
During the Year | | |
Year over Year Average
Change in Fair Value
of Outstanding and
Unvested Equity Awards
Granted in Prior Years | | |
Year over Year
Average Change in
Fair Value of Equity
Awards Granted
in Prior Years that
Vested in the Year | | |
Average Value of
Dividend Equivalents
Accrued or Other
Earnings Paid on Stock
Awards Not Otherwise
Reflected in Fair Value | | |
Total Average
Equity Award
Adjustments | |
| |
2023 | |
$ | 3,955,902 | | |
$ | (789,322) | | |
$ | (879,498) | | |
$ | 403,117 | | |
$ | 2,690,199 | |
| |
2022 | |
$ | 11,751,514 | | |
$ | 3,365,229 | | |
$ | (289,102) | | |
$ | 441,169 | | |
$ | 15,268,810 | |
| |
2021 | |
$ | 4,989,853 | | |
$ | 1,461,574 | | |
$ | 271,571 | | |
$ | 315,938 | | |
$ | 7,038,936 | |
| |
2020 | |
$ | 2,488,166 | | |
$ | (365,446) | | |
$ | 269,145 | | |
$ | 204,866 | | |
$ | 2,596,731 | |
| (5) |
Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement
period, assuming dividend reinvestment, and the difference between our share price at the end of each year shown and the beginning
of the measurement period by our share price at the beginning of the measurement period. The beginning of the measurement
period for each year in the table is December 31, 2019. |
| (6) |
The peer group used for this purpose is the Nasdaq Biotechnology Index. |
| (7) |
The dollar amounts reported represent the amount of net income reflected in our Consolidated Statements of Income included
in our Annual Report on Form 10-K for the applicable year. Included in our net income for 2020 was a $4.5 billion charge to
acquired in-process research and development (“IPR&D”) expense recorded in connection with our acquisition
of Forty Seven, Inc. Our 2022 net income included a $2.7 billion partial impairment charge related to certain IPR&D assets
acquired from Immunomedics, Inc. |
| (8) |
The dollar amounts reported represent the amount of net product sales revenue reflected in our Consolidated Statements
of Income included in our Annual Report on Form 10-K for the applicable year. Total full year 2023 product sales of $26.9
billion were relatively flat compared to the same period in 2022, with lower Veklury sales largely offset by higher HIV and
Oncology sales. Total product sales, excluding Veklury, increased 7% to $24.7 billion in the full year 2023 compared to 2022,
primarily driven by higher HIV and Oncology sales. |
|
|
|
|
| Company Selected Measure Name |
|
Net Product Revenue
|
|
|
|
| Named Executive Officers, Footnote [Text Block] |
|
| (1) |
The dollar amounts reported are the amounts reported in the “Total” column
of the Summary Compensation Table for our Chairman and Chief Executive Officer, Mr. O’Day. |
| (3) |
The dollar amounts reported represent the average of the amounts reported for
our NEOs as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable
year. The NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2023
and 2022, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Deborah H. Telman; and (ii) for 2021 and 2020, Andrew
D. Dickinson, Johanna Mercier, Merdad V. Parsey and Brett A. Pletcher. |
|
|
|
|
| Peer Group Issuers, Footnote [Text Block] |
|
| (6) |
The peer group used for this purpose is the Nasdaq Biotechnology Index. |
|
|
|
|
| Adjustment To PEO Compensation, Footnote [Text Block] |
|
| (2) |
The dollar amounts reported represent the amount of “compensation actually paid”, as
computed in accordance with SEC rules, for Mr. O’Day. The dollar amounts do not reflect the actual amount of compensation
earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were made to total compensation
to determine the compensation actually paid: |
| |
Year | |
Summary
Compensation Table
Total for Mr. O’Day | | |
Less: Summary
Compensation
Table Reported
Value of Equity
Awards(a) | | |
Plus: Equity Award
Adjustments(b) | | |
Equals: Compensation
Actually Paid to Mr. O’Day | |
| |
2023 | |
$ | 22,607,690 | | |
$ | 15,615,056 | | |
$ | 8,491,149 | | |
$ | 15,483,783 | |
| |
2022 | |
$ | 21,621,253 | | |
$ | 14,353,915 | | |
$ | 47,697,917 | | |
$ | 54,965,255 | |
| |
2021 | |
$ | 19,229,466 | | |
$ | 13,139,064 | | |
$ | 25,394,946 | | |
$ | 31,485,348 | |
| |
2020 | |
$ | 18,998,095 | | |
$ | 11,513,097 | | |
$ | 8,632,324 | | |
$ | 16,117,322 | |
| |
(a) |
Represents the aggregate grant-date fair value of equity awards as reported in the
“Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year. |
| |
(b) |
The equity award adjustments for each applicable year were as set forth in the table below. The
valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The
amounts deducted or added in calculating the equity award adjustments are as follows: |
| |
Year | |
Year End
Fair Value of
Equity Awards
Granted during
the Year | | |
Year over Year
Change in Fair Value
of Outstanding and
Unvested Equity Awards
Granted in Prior Years | | |
Year over Year Change
in Fair Value of Equity
Awards Granted
in Prior Years that
Vested in the Year | | |
Value of Dividend
Equivalents Accrued
or Other Earnings Paid
on Stock Awards Not
Otherwise Reflected
in Fair Value | | |
Total Equity
Award
Adjustments | |
| |
2023 | |
$ | 12,525,814 | | |
$ | (2,481,113) | | |
$ | (2,859,625) | | |
$ | 1,306,073 | | |
$ | 8,491,149 | |
| |
2022 | |
$ | 34,153,918 | | |
$ | 14,183,571 | | |
$ | (1,966,582) | | |
$ | 1,327,010 | | |
$ | 47,697,917 | |
| |
2021 | |
$ | 17,162,219 | | |
$ | 6,011,125 | | |
$ | 707,262 | | |
$ | 1,514,340 | | |
$ | 25,394,946 | |
| |
2020 | |
$ | 8,885,442 | | |
$ | (1,693,496) | | |
$ | 409,911 | | |
$ | 1,030,467 | | |
$ | 8,632,324 | |
|
|
|
|
| Non-PEO NEO Average Total Compensation Amount |
[1] |
$ 7,588,163
|
$ 7,874,828
|
$ 6,279,776
|
$ 6,616,768
|
| Non-PEO NEO Average Compensation Actually Paid Amount |
[2] |
$ 5,469,137
|
18,182,586
|
9,693,178
|
6,126,435
|
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] |
|
| (4) |
The dollar amounts reported represent the average amount of “compensation
actually paid” to the NEOs identified in footnote 3, as computed in accordance with SEC rules. The dollar amounts do
not reflect the actual amount of compensation earned by or paid to any NEO during the applicable year. In accordance with
the SEC rules, the following adjustments were made to average total compensation for the NEOs for each year to determine the
compensation actually paid: |
| |
Year | |
Average
Reported Summary
Compensation Table
Total for Other NEOs | | |
Less: Summary
Compensation Table
Average Reported
Value of Equity Awards | | |
Plus: Average
Equity Award
Adjustments(a) | | |
Equals: Average
Compensation Actually
Paid to Other NEOs | |
| |
2023 | |
$ | 7,588,163 | | |
$ | 4,809,225 | | |
$ | 2,690,199 | | |
$ | 5,469,137 | |
| |
2022 | |
$ | 7,874,828 | | |
$ | 4,961,052 | | |
$ | 15,268,810 | | |
$ | 18,182,586 | |
| |
2021 | |
$ | 6,279,776 | | |
$ | 3,625,534 | | |
$ | 7,038,936 | | |
$ | 9,693,178 | |
| |
2020 | |
$ | 6,616,768 | | |
$ | 3,087,064 | | |
$ | 2,596,731 | | |
$ | 6,126,435 | |
| |
(a) |
The amounts deducted or added in calculating the total average equity award adjustments are as follows: |
| |
Year | |
Average Year End
Fair Value of Equity
Awards Granted
During the Year | | |
Year over Year Average
Change in Fair Value
of Outstanding and
Unvested Equity Awards
Granted in Prior Years | | |
Year over Year
Average Change in
Fair Value of Equity
Awards Granted
in Prior Years that
Vested in the Year | | |
Average Value of
Dividend Equivalents
Accrued or Other
Earnings Paid on Stock
Awards Not Otherwise
Reflected in Fair Value | | |
Total Average
Equity Award
Adjustments | |
| |
2023 | |
$ | 3,955,902 | | |
$ | (789,322) | | |
$ | (879,498) | | |
$ | 403,117 | | |
$ | 2,690,199 | |
| |
2022 | |
$ | 11,751,514 | | |
$ | 3,365,229 | | |
$ | (289,102) | | |
$ | 441,169 | | |
$ | 15,268,810 | |
| |
2021 | |
$ | 4,989,853 | | |
$ | 1,461,574 | | |
$ | 271,571 | | |
$ | 315,938 | | |
$ | 7,038,936 | |
| |
2020 | |
$ | 2,488,166 | | |
$ | (365,446) | | |
$ | 269,145 | | |
$ | 204,866 | | |
$ | 2,596,731 | |
|
|
|
|
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] |
|
Compensation Actually Paid Versus TSR 2020 – 2023
|
|
|
|
| Compensation Actually Paid vs. Net Income [Text Block] |
|
Compensation Actually Paid Versus Net Income 2020 – 2023
|
|
|
|
| Compensation Actually Paid vs. Company Selected Measure [Text Block] |
|
Compensation Actually Paid Versus Net Revenue 2020 –
2023
|
|
|
|
| Total Shareholder Return Vs Peer Group [Text Block] |
|
Compensation Actually Paid Versus TSR 2020 – 2023
|
|
|
|
| Tabular List [Table Text Block] |
|
Financial Performance Measures
As described in greater detail in “Executive Compensation –
Compensation Discussion and Analysis” on page 45, our executive compensation program reflects a pay-for-performance philosophy,
with a focus not only on the successful progression of research programs, clinical trials and the launch of new products but also
on performance across a range of shorter-term metrics that advance our long-term strategy and longer-term value creation for our
stockholders. The metrics that we use for both our long-term and short-term incentive awards are selected based on an objective
of incentivizing our NEOs to increase the value of our company for our stockholders. As required by Item 402(v), the most important
financial performance measures used by the Company to link executive compensation actually paid to the NEOs, for the most recently
completed fiscal year, to the Company’s performance are as follows:
| |
a. |
Net Product Revenue |
| |
b. |
Relative TSR |
| |
c. |
Non-GAAP Operating Income |
|
|
|
|
| Total Shareholder Return Amount |
[3] |
$ 147
|
150
|
121
|
93
|
| Peer Group Total Shareholder Return Amount |
[4] |
119
|
114
|
126
|
126
|
| Net Income (Loss) Attributable to Parent |
[5] |
$ 5,613,000,000
|
$ 4,566,000,000
|
$ 6,201,000,000
|
$ 89,000,000
|
| Company Selected Measure Amount |
[6] |
26,934,000,000
|
26,982,000,000
|
27,008,000,000
|
24,355,000,000
|
| PEO Name |
|
Mr. O’Day
|
Mr. O’Day
|
Mr. O’Day
|
Mr. O’Day
|
| Measure [Axis]: 1 |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Measure Name |
|
Net Product Revenue
|
|
|
|
| Measure [Axis]: 2 |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Measure Name |
|
Relative TSR
|
|
|
|
| Measure [Axis]: 3 |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Measure Name |
|
Non-GAAP Operating Income
|
|
|
|
| PEO [Member] | Less: Summary Compensation Table Reported Value of Equity Awards |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
[7] |
$ 15,615,056
|
$ 14,353,915
|
$ 13,139,064
|
$ 11,513,097
|
| PEO [Member] | Plus: Equity Award Adjustments |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
[8] |
8,491,149
|
47,697,917
|
25,394,946
|
8,632,324
|
| PEO [Member] | Year End Fair Value of Equity Awards Granted during the Year |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
|
12,525,814
|
34,153,918
|
17,162,219
|
8,885,442
|
| PEO [Member] | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
|
(2,481,113)
|
14,183,571
|
6,011,125
|
(1,693,496)
|
| PEO [Member] | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
|
(2,859,625)
|
(1,966,582)
|
707,262
|
409,911
|
| PEO [Member] | Value of Dividend Equivalents Accrued or other Earnings Paid on Stock Awards not Otherwise Reflected in Fair Value |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
|
1,306,073
|
1,327,010
|
1,514,340
|
1,030,467
|
| PEO [Member] | Total Equity Award Adjustments |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
|
8,491,149
|
47,697,917
|
25,394,946
|
8,632,324
|
| Non-PEO NEO [Member] | Less: Summary Compensation Table Average Reported Value of Equity Awards |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
|
4,809,225
|
4,961,052
|
3,625,534
|
3,087,064
|
| Non-PEO NEO [Member] | Plus: Average Equity Award Adjustments |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
[9] |
2,690,199
|
15,268,810
|
7,038,936
|
2,596,731
|
| Non-PEO NEO [Member] | Average Year End Fair Value of Equity Awards Granted during the Year |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
|
3,955,902
|
11,751,514
|
4,989,853
|
2,488,166
|
| Non-PEO NEO [Member] | Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
|
(789,322)
|
3,365,229
|
1,461,574
|
(365,446)
|
| Non-PEO NEO [Member] | Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
|
(879,498)
|
(289,102)
|
271,571
|
269,145
|
| Non-PEO NEO [Member] | Average Value of Dividend Equivalents Accrued or other Earnings Paid on Stock Awards not Otherwise Reflected in Fair Value |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
|
403,117
|
441,169
|
315,938
|
204,866
|
| Non-PEO NEO [Member] | Total Average Equity Award Adjustments |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| Adjustment to Compensation Amount |
|
2,690,199
|
15,268,810
|
7,038,936
|
2,596,731
|
| Mr. O'Day |
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
| PEO Total Compensation Amount |
[10] |
22,607,690
|
21,621,253
|
19,229,466
|
18,998,095
|
| PEO Actually Paid Compensation Amount |
[11] |
$ 15,483,783
|
$ 54,965,255
|
$ 31,485,348
|
$ 16,117,322
|
|
|